ALEXION PHARMACEUTICALS WIDENS 1Q LOSS

Alexion Pharmaceuticals Inc., a developer of investigative treatments for cardiovascular and other diseases, on Tuesday posted a wider first-quarter loss as the cost of research and development surged.Losses totaled $35.1 million, or $1.16 per share, compared with $19.2 million, or 70 cents per share, in the same period last year. Contract research revenue increased to $460,000 from $147,000 a year ago, boosted by larger government-funded research grants.

Schaeffers Research (http://www.schaeffersresearch.com/commentary/news_detail_ap.aspx?click=home&newsid=111542)